Latest Non Dilutive Funding News

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.

Algorae Pharmaceuticals strengthened its balance sheet with $5.47 million cash reserves and broadened its commercial footprint through new licensing deals and AI-driven drug validation.

Premier1 Lithium completed its maiden RC drilling at Yalgoo and confirmed expanded gold anomalies at Rochefort through advanced geophysical surveys, setting up follow-up drilling in 2026.

Latitude 66 has locked in exploration permits for its high-grade KSB gold-cobalt project in Finland following a key legislative amendment, while its Laverton drilling campaign in Western Australia continues to reveal promising gold mineralisation with potential for resource growth.

Talga Group reported record anode production at its EVA plant and significant progress on its 5,000tpa Vittangi anode plant FEED study, alongside strategic partnerships and exploration breakthroughs.

Actinogen Medical’s pivotal XanaMIA trial clears a key interim hurdle with the Data Monitoring Committee endorsing continuation, while a $16.8 million capital raise and non-dilutive funding bolster its balance sheet ahead of final results due November 2026.

Alicanto Minerals has kicked off a 50,000-metre drilling campaign to expand the 915,000oz Mt Henry gold resource, backed by a fresh $18.1 million non-dilutive funding package and key leadership changes.

Argenica Therapeutics is progressing its ARG-007 drug toward a targeted Phase 2b trial for acute ischaemic stroke, leveraging AI for patient selection and securing key regulatory approvals, while maintaining a solid cash position of $8 million.

Litchfield Minerals secured US$500,000 from BHP's Xplor program and delivered thick copper-zinc intercepts at Oonagalabi, expanding its mineral system model despite operational challenges.

Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.

Entropy Neurodynamics has reported encouraging early clinical outcomes from its pioneering intravenous psilocin therapy for Binge Eating Disorder, alongside a patent grant that strengthens its intellectual property moat.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.